Improving cardiovascular health in dialysis patients using a structured programme of exercise (CYCLE-HD)

ISRCTN ISRCTN11299707
DOI https://doi.org/10.1186/ISRCTN11299707
Secondary identifying numbers CPMS 17951
Submission date
04/03/2015
Registration date
05/03/2015
Last edited
29/07/2024
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Urological and Genital Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
We are carrying out a study of 130 haemodialysis patients to investigate the effects of 30 minutes of cycling exercise, three times per week during dialysis. Research has shown that exercise outside of a dialysis session can significantly improve fitness and heart function. However, exercise whilst on dialysis has a number of potential effects on the heart and so the long term consequences of this need to be studied. The aim of this study is therefore to monitor the immediate and long term effects of exercise on dialysis on patients heart and quality of life. The study's findings should help to improve the well-being of future haemodialysis patients by making exercise more available on dialysis units in the UK.

Who can participate?
The CYCLE-HD study aims to recruit 130 haemodialysis patients from a number of haemodialysis units across the Leicester Renal Network.

What does the study involve?
This study will investigate the effects of a 6 month programme of exercise during dialysis. Patients who dialyse on certain shifts take part in the exercise programme, and those on other shifts carry on as usual, without exercising to compare. Patients chosen to undertake exercise use a specially designed exercise bike for 30 minutes during routine dialysis sessions. Both of these groups are very important to the research study, as this will allow us to measure the effects of doing exercise in comparison to not doing exercise. The exercise and non-exercise shifts are decided randomly and patients are not be able to choose which group they are in. All the people taking part in both the exercise and the control groups undergo a set of assessments at the beginning and the end of the study. These takes place over one or two days depending on patients preference. Some of these assessments are also done in the middle of the study. They include measuring fitness levels, looking at the structure of the heart and how it well it works, daily levels of activity, height and weight, and some questionnaires.

What are the possible benefits and risks of participating?
There are no direct benefits to taking part in this research, although we anticipate that the exercise training sessions will help participants get fitter. We hope that the results of the study will help us design improved treatments for other kidney patients in the future. Our pilot work has shown no evidence of any side effects or adverse event of doing exercise while on dialysis. The main risk is from the use of adenosine during the cardiac MRI scans as patients can get symptoms similar to that of exercise like mild breathlessness, flushing and palpitations. These are very short lived however and patients can choose not to have the adenosine injection if they wish.

Where is the study run from?
The CYCLE-HD study has been set up by the University of Leicester and University Hospitals of Leicester NHS Trust from where it will run.

When is study starting and how long is it expected to run for?
February 2015 to June 2018

Who is funding the study?
National Institute of Health Research (UK)

Who is the main contact?
Dr James Burton

Contact information

Dr James Burton
Public

Department of Infection, Immunity and Inflammation
Maurice Shock Medical Sciences Building
University Road
Leicester
LE1 9HN
United Kingdom

Phone +44 (0)116 2584042
Email dsm12@le.ac.uk

Study information

Study designRandomized; Interventional; Design type: Treatment
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use contact details to request a patient information sheet
Scientific titleA randomised, cluster controlled trial to investigate the effects of a programme of intradialytic exercise on cardiovascular outcomes in haemodialysis patients.
Study acronymCYCLE-HD
Study objectivesWe hypothesise that an intradialytic program of exercise:
1. Leads to a regression in left ventricular mass
2. Is safe with no increase in either cardiac arrhythmias or cardiac fibrosis
3. Leads to an improvement in cardiovascular indices associated with an increased risk and cardiovascular disease and sudden cardiac death.
Ethics approval(s)NRES Committee East Midlands - Northampton, 31/10/2014, ref: 14/EM/1190
Health condition(s) or problem(s) studiedTopic: Renal disorders; Subtopic: Renal disorders; Disease: All Renal disorders
InterventionThe study will compare six month of cycling exercise during dialysis (intervention group) against normal dialysis care (no intervention). The intervention group will use specially adapted and calibrated exercise bicycles three times a week during dialysis, aiming for 30 minutes continuous cycling at a level perceived by patients as 'somewhat hard'. This is set on an individual basis after an assessment with a trained member of staff and is then adjusted as required to progress training. Our pilot exercise programme has been well tolerated with no adverse symptoms reported in any of the exercising patients. It is accessible to patients of different age, gender, culture and ethnicity.
Intervention typeBehavioural
Primary outcome measureReduction in left ventricular mass; Timepoint(s): Measured at baseline and after 6-months of exercise intervention.
Secondary outcome measures1. Measurements of cardiac structure and function measured using MRI and echocardiography (e.g. left ventricular ejection fraction, blood oxygen delivery)
2. Cardiac rhythm measured using 48 hour ambulatory monitoring
3. Non-invasive cardiac measurements (e.g.blood pressure)
4. Measurements of height, weight, waist circumference and body composition analysis
5. Physical functioning measures including walking and standing tests
6. Objective assessment of habitual physical activity using accelerometry
7. Quality of life and perceived function scores using a variety of validated questionnaires
8. Blood markers of myocardial dysfunction and risk
9. Blood markers of the malnutrition and inflammation
Overall study start date01/02/2014
Completion date31/01/2019

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participantsPlanned Sample Size: 130; UK Sample Size: 130; Description: To have 80% power to detect a difference between treatment and control groups of a reduction in LV mass of 15g, with an attrition rate of 10%, 65 patients are required in each group.
Total final enrolment130
Key inclusion criteria1. Be a prevalent haemodialysis patient (on haemodialysis for more than 3 months)
2. Age 18 years or older
3. Able and willing to give informed consent
Key exclusion criteria1. Unable to participate in current exercise program due to perceived physical or psychological barriers
2. Unable to undergo MRI scanning (metal implants / prostheses, claustrophobia etc.)
3. Unfit to undertake exercise according to the American College of Sports Medicine guidelines
4. Contraindications to exercise testing (35) that include:
4.1. Recent significant change in resting ECG that suggests significant ischaemia, recent myocardial infarction (2 weeks) or other acute cardiac event;
4.2. Unstable angina;
4.3. Uncontrolled cardiac dysrhythmias causing symptoms or haemodynamic compromise;
4.4. Symptomatic severe aortic stenosis
4.5. Uncontrolled symptomatic heart failure
4.6. Acute pulmonary embolus or pulmonary infarction
4.7. Acute myocarditis or pericarditis
4.8. Suspected or known dissecting aneurysm
4.9. Acute systemic infection, accompanied by fever, body aches or swollen lymph glands
5. Age <18 years
6. Unable or unwilling to give informed consent
Date of first enrolment16/03/2015
Date of final enrolment07/03/2018

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

University of Leicester
Department of Infection, Immunity and Inflammation
Maurice Shock Medical Sciences Building
University Road
Leicester
LE1 9HN
United Kingdom

Sponsor information

University of Leicester (UK)
Hospital/treatment centre

Gwendolen Road
Leicester
LE5 4PW
England
United Kingdom

ROR logo "ROR" https://ror.org/04h699437

Funders

Funder type

Government

National Institute for Health Research
Government organisation / National government
Alternative name(s)
National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR
Location
United Kingdom

Results and Publications

Intention to publish date31/12/2020
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planMethodology data, including reproducibility of imaging techniques, as will the data on cardiac rhythm will be published within the first 18 months. Baseline cross-sectional data, including cardiac and physical function, will be published around 6 months after recruitment has closed. We anticipate publication of the primary outcome data within 12 months of the end of the trial.
IPD sharing planDeidentified individual participant data collected for the study, and a data dictionary defining each field in the set, will be made available to others on specific to request to the chief investigator (Prof. James Burton [dsm12@le.ac.uk]) provided all regulatory and data sharing approvals are obtained after. This request should include a pre-specified analysis plan. These data will be available after publication of the primary study findings. There is no time limit for such requests.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol article protocol 08/07/2016 Yes No
Basic results 20/01/2020 20/01/2020 No No
Protocol file version V4 27/06/2016 17/12/2020 No No
Results article Effects on left ventricular mass 01/06/2021 04/05/2021 Yes No
Results article Effect of cycling on microparticles or circulating markers of systemic inflammation 02/12/2021 03/12/2021 Yes No
Other publications Feasibility substudy in frail patients 03/11/2020 25/07/2022 Yes No
HRA research summary 28/06/2023 No No
Other publications Cost-effective analysis 08/04/2021 08/04/2024 Yes No
Other publications Defining myocardial fibrosis in haemodialysis patients with non-contrast cardiac magnetic resonance 13/07/2018 08/04/2024 Yes No
Other publications The cardiovascular determinants of physical function in patients with end-stage kidney disease on haemodialysis 30/11/2020 08/04/2024 Yes No
Other publications The reliability and feasibility of non-contrast adenosine stress cardiovascular magnetic resonance T1 mapping in patients on haemodialysis 08/06/2020 08/04/2024 Yes No
Other publications Impact of physical activity on surrogate markers of cardiovascular disease 28/06/2024 29/07/2024 Yes No

Additional files

ISRCTN11299707_BasicResults_20Jan20.pdf
Uploaded 20/01/2020
ISRCTN11299707_PROTOCOL_V4_27June16.doc
Uploaded 17/12/2020

Editorial Notes

29/07/2024: Publication references added.
08/04/2024: Publication references added.
25/07/2022: Publication reference added.
03/12/2021: Publication reference added.
04/05/2021: Publication reference added.
17/12/2020: Uploaded protocol Version 4, 27 June 2016 (not peer reviewed).
03/09/2020: The intention to publish date was changed from 31/03/2020 to 31/12/2020.
20/01/2020: The following changes were made to the trial record:
1. IPD sharing statement updated
2. Total final enrolment number added.
3. The basic results of this trial have been uploaded as an additional file
17/01/2020: The intention to publish date was changed from 31/01/2020 to 31/03/2020.
16/04/2018: The recruitment end date was changed from 30/06/2018 to 07/03/2018, IPD sharing statement added.
11/07/2016: Publication reference added.